Various zwitterionicpolymers, sulfobetaine and phosphoryl choline derivatives were synthesized in order to investigate zwitterionicpolymer structures toward surface modification of PDMS, where the adsorption of zwitterionicpolymers on polydimethylsiloxane surface treated with air-plasma was induced by the electrostatic interaction,. The electrostatic interaction was evaluated with hydrophilicity
Synthesis and study of photochromic properties of copolymers based on functionalized chromenes
作者:V. P. Grachev、G. M. Bakova、L. I. Makhonina、E. A. Yurieva、S. M. Aldoshin、A. M. Gorelik、V. A. Barachevskii
DOI:10.1007/s11172-011-0219-3
日期:2011.7
Chromenes functionalized with methacryl groups were synthesized and involved into the radical polymerization to obtain copolymers with ethyl acrylate. Comparison of spectral kinetic characteristics of poly(methyl methacrylate) glasses containing chromenes and photochromic copolymers as additives led to a conclusion that incorporation of a photochromic compound as a part of a copolymer into the polymeric glass increases efficiency of photocoloration of photochromic compounds in the polymeric layer.
[EN] COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION DE POLYMÈRES EN ÉTOILE POUR L'AFFICHAGE DE LIGAND ET/OU L'ADMINISTRATION DE MÉDICAMENT
申请人:AVIDEA TECH INC
公开号:WO2020214858A1
公开(公告)日:2020-10-22
A star polymer of formula O[P1]-([X]-A[P2]-[Z]-[P3])n where O is a core; A is a polymer arm attached to the core; X is a linker molecule between the core and the polymer arm; Z is a linker molecule between the end of the polymer arm and P3; P1, P2 and P3 are each independently one or more pharmaceutically active compounds that act extracellularly or intracellularly, n is an integer number; [ ] denotes that the group is optional; and at least one of P1, P2 or P3 is present.
Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction
作者:Geoffrey M. Lynn、Petr Chytil、Joseph R. Francica、Anna Lagová、Gray Kueberuwa、Andrew S. Ishizuka、Neeha Zaidi、Ramiro A. Ramirez-Valdez、Nicolas J. Blobel、Faezzah Baharom、Joseph Leal、Amy Q. Wang、Michael Y. Gerner、Tomáš Etrych、Karel Ulbrich、Leonard W. Seymour、Robert A. Seder、Richard Laga
DOI:10.1021/acs.biomac.8b01473
日期:2019.2.11
Small molecule Toll-like receptor-7 and -8 agonists (TLR-7/8a) can be used as vaccine adjuvants to induce CD8 T cell immunity but require formulations that prevent systemic toxicity and focus adjuvant activity in lymphoid tissues. Here, we covalently attached TLR-7/8a to polymers of varying composition, chain architecture and hydrodynamic behavior (∼300 nm submicrometer particles, ∼10 nm micelles and ∼4 nm flexible random coils) and evaluated how these parameters of polymer-TLR-7/8a conjugates impact adjuvant activity in vivo. Attachment of TLR-7/8a to any of the polymer compositions resulted in a nearly 10-fold reduction in systemic cytokines (toxicity). Moreover, both lymph node cytokine production and the magnitude of CD8 T cells induced against protein antigen increased with increasing polymer-TLR-7/8a hydrodynamic radius, with the submicrometer particle inducing the highest magnitude responses. Notably, CD8 T cell responses induced by polymer-TLR-7/8a were dependent on CCR2+ monocytes and IL-12, whereas responses by a small molecule TLR-7/8a that unexpectedly persisted in vaccine-site draining lymph nodes (T1/2 = 15 h) had less dependence on monocytes and IL-12 but required Type I IFNs. This study shows how modular properties of synthetic adjuvants can be chemically programmed to alter immunity in vivo through distinct immunological mechanisms.
申请人:Deutsches Krebsforschungszentrum
Stiftung des öffentlichen Rechts
公开号:EP1647283A1
公开(公告)日:2006-04-19
The present invention relates to a contrast agent comprising a copolymer having at least a first monomer unit which comprises a metal chelating moiety and a second monomer unit without a chelating moiety and a contrast enhancing metal bound to the chelating moiety.
The invention also relates to a process for the preparation of such a contrast agent and the use in magnetic resonance imaging (MRI).